Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone

Italian Journal of Pediatrics

Volumn 38, Issue 1, 2012, Pages

  Tolone, Salvatore ^a   Pellino, Valeria ^a   Vitaliti, Giovanna ^b   Lanzafame, Angela ^b   Tolone, Carlo ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Department of Medical and Pediatrics Science ^*  (Italy)

Author keywords

Children gastritis; H.P; H.P. eradication; Probiotic

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LACTOFERRIN; OMEPRAZOLE; PROBIOTIC AGENT;

ARTICLE; CHILD; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; EPIGASTRIC PAIN; ERADICATION THERAPY; FEMALE; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; PATIENT COMPLIANCE; PEDIATRICS; SCHOOL CHILD; UREA BREATH TEST; VOMITING;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTOFERRIN; MALE; PROBIOTICS; TREATMENT OUTCOME;

EID: 84868249208     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: 10.1186/1824-7288-38-63     Document Type: Article

References (41)

1. Helicobacter pylori infection. Suerbaum S, Michetti P, N Engl J Med 2002 347 1175 1186 10.1056/NEJMra020542 12374879
2. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G, European Helicobacter Pylori Study Group (EHPSG), Aliment Pharmacol Ther 2002 16 167 180 11966537
3. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology, Am J Gastroenterol 2007 102 1808 1825 10.1111/j.1572-0241.2007.01393.x 17608775
4. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ, Gut 2007 56 772 781 10.1136/gut.2006.101634 17170018
5. Age-dependent eradication of Helicobacter pylori in Japanese patients. Mamori S, Higashida A, Kawara F, Ohnishi K, Takeda A, Senda E, Ashida C, Yamada H, World J Gastroenterol 2010 16 4176 4179 10.3748/wjg.v16.i33.4176 20806435
6. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Gotteland M, Brunser O, Cruchet S, Aliment Pharmacol Ther 2006 23 1077 1086 10.1111/j.1365-2036.2006.02868.x 16611267
7. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD, Aliment Pharmacol Ther 2007 25 155 168 17229240
8. Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication. Ozdil K, Calhan T, Sahin A, Senates E, Kahraman R, Yzbasioglu B, Demirdag H, Demirsoy H, Sökmen MH, Hepatogastroenterology 2011 58 1148 1152 10.5754/hge11075 21937367
9. Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Tursi A, Brandimarte G, Giorgetti GM, Modeo ME, Med Sci Monit 2004 10 R662 CR666 15567983
10. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Medeiros JA, Gonçalves TM, Boyanova L, Pereira MI, de Carvalho JN, Pereira AM, Cabrita AM, Eur J Clin Microbiol Infect Dis 2011 30 555 559 10.1007/s10096-010-1119-4 21207091
11. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Szajewska H, Horvath A, Piwowarczyk A, Aliment Pharmacol Ther 2010 32 1069 1079 10.1111/j.1365-2036.2010.04457.x 21039671
12. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Chenoll E, Casinos B, Bataller E, Astals P, Echevarría J, Iglesias JR, Balbarie P, Ramón D, Genovés S, Appl Environ Microbiol 2011 77 1335 1343 10.1128/AEM.01820-10 21169430
13. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Wilhelm SM, Johnson JL, Kale-Pradhan PB, Ann Pharmacother 2011 45 960 966 10.1345/aph.1Q104 21693698
14. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Boscarelli G, Piscitelli D, Amoruso A, Di Leo A, Miniello VL, Francavilla A, et al. Gastroenterology 2005 129 1414 1419 10.1053/j.gastro.2005.09.007 16285942
15. Results from the pediatric European register for treatment of Helicobacter pylori (PERTH). Oderda G, Shcherbakov P, Bontems P, Urruzuno P, Romano C, Gottrand F, Gómez MJ, Ravelli A, Gandullia P, Roma E, European Pediatric Task Force on Helicobacter pylori, et al. Helicobacter 2007 12 150 156 10.1111/j.1523-5378.2007.00485.x 17309752
16. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. Lionetti E, Indrio F, Pavone L, Borrelli G, Cavallo L, Francavilla R, Helicobacter 2010 15 79 87 10.1111/j.1523-5378.2009.00743.x 20402810
17. Concordance of Helicobacter pylori strains within families. Kivi M, Tindberg Y, Sörberg M, Casswall TH, Befrits R, Hellström PM, Bengtsson C, Engstrand L, Granström M, J Clin Microbiol 2003 41 5604 5608 10.1128/JCM.41.12.5604-5608.2003 14662948
18. Helicobacter pylori infection and the development of gastric cancer. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ, N Engl J Med 2001 345 784 789 10.1056/NEJMoa001999 11556297
19. Results of triple eradication therapy in Japanese children: a retrospective multicenter study. Kato S, Konno M, Maisawa S, Tajiri H, Yoshimura N, Shimizu T, Toyoda S, Nakayama Y, Iinuma K, J Gastroenterol 2004 39 838 843 10.1007/s00535-004-1398-6 15565402
20. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Song MJ, Park DI, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Helicobacter 2010 15 206 213 10.1111/j.1523-5378.2010.00751.x 20557362
21. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JS, Jung HC, Song IS, Helicobacter 2008 13 261 268 10.1111/j.1523-5378. 2008.00601.x 18665934
22. Helicobacter pylori therapy in children: overview and challenges. Chiesa C, Pacifico L, Anania C, Poggiogalle E, Chiarelli F, Osborn JF, Int J Immunopathol Pharmacol 2010 23 405 416 20646336
23. Review article: Probiotics in gastrointestinal and liver diseases. Jonkers D, Stockbrgger R, Aliment Pharmacol Ther 2007 26 133 148 18081657
24. Atopic disease, immune and environment. Leonardi S, Miraglia del Giudice M, La Rosa M, Bellanti J, Allergy Asthma Proc 2007 28 410 417 10.2500/aap.2007.28.2954 17883908
25. Probiotics in the atopic march: highlights and new insights. del Giudice MM, Rocco A, Capristo C, Dig Liv Dis 2006 38 288 S290
26. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. McFarland LV, World J Gastroenterol 2010 16 2202 2222 10.3748/wjg.v16.i18.2202 20458757
27. Role of probiotics in patients with Helicobacter pylori infection. Franceschi F, Cazzato A, Nista EC, Scarpellini E, Roccarina D, Gigante G, Gasbarrini G, Gasbarrini A, Helicobacter 2007 12 59 63 10.1111/j.1523-5378.2007. 00565.x 17991178
28. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetti V, Cammarota G, Anti M, De Lorenzo A, Pola P, et al. Aliment Pharmacol Ther 2001 15 163 169 10.1046/j.1365-2036.2001.00923.x 11148433
29. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, Nista EC, Cammarota G, Gasbarrini G, Gasbarrini A, Am J Gastroenterol 2002 97 2744 2749 10.1111/j.1572-0241.2002.07063.x 12425542
30. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy-a placebo-controlled, double-blind randomized pilot study. Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H, Rautelin H, Korpela R, Aliment Pharmacol Ther 2005 21 1263 1272 10.1111/j.1365-2036.2005.02448.x 15882248
31. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Lionetti E, Miniello VL, Castellaneta SP, Magistá AM, de Canio A, Maurogiovanni G, Ierardi E, Cavallo L, Francavilla R, Aliment Pharmacol Ther 2006 24 1461 1468 10.1111/j.1365-2036.2006.03145.x 17032283
32. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y, Acta Paediatr 2009 98 127 131 10.1111/j.1651-2227.2008.00977.x 18681892
33. Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. Szajewska H, Albrecht P, Topczewska-Cabanek A, J Pediatr Gastroenterol Nutr 2009 48 431 436 10.1097/MPG.0b013e318182e716 19330931
34. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. Goldman CG, Barrado DA, Balcarce N, Rua EC, Oshiro M, Calcagno ML, Janjetic M, Fuda J, Weill R, Salgueiro MJ, et al. Nutrition 2006 22 984 988 10.1016/j.nut.2006.06.008 16978844
35. Efficacy of Probinul in reduction of antibiotic gastro-intestinal related side effects in children with respiratory infections. Tolone C, Proceeding of 62° National Congress of Italian Society of Pediatrics 2006 22826929
36. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. de Bortoli N, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F, Mumolo MG, Ricchiuti A, Cristiani F, Santi S, et al. Am J Gastroenterol 2007 102 951 956 10.1111/j.1572-0241.2007.01085.x 17313499
37. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Fukushima Y, Kawata Y, Hara H, Terada A, Mitsuoka T, Int J Food Microbiol 1998 42 39 44 10.1016/S0168-1605(98)00056-7 9706796
38. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. Smythies LE, Waites KB, Lindsey JR, Harris PR, Ghiara P, Smith PD, J Immunol 2000 165 1022 1029 10878379
39. The role of probiotics in the clinical management of food allergy and atopic dermatitis. del Giudice M, De Luca MG, J Clin Gastroenterol 2004 38 6 Suppl 84 S85 15220666
40. Food allergy and probiotics in childhood. Del Giudice MM, Leonardi S, Maiello N, Brunese FP, J Clin Gastroenterol 2010 44 22 S25 20562632
41. Is there a benefit extending the duration of Helicobacter Pylori sequential therapy to 14 days? Hsu PI, Wu DC, Wu JY, Graham DY, Helicobacter 2011 16 146 152 10.1111/j.1523-5378.2011.00829.x 21435093